Vitamin D transport proteins megalin and disabled-2 are expressed in prostate and colon epithelial cells and are induced and activated by all- trans -retinoic acid

Nutrition and Cancer

Volumn 65, Issue 6, 2013, Pages 900-907

  Ternes, Shantel B ^a   Rowling, Matthew J ^a  

^a IOWA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIFEDIOL; CARRIER PROTEIN; DISABLED 2 PROTEIN; MEGALIN; RETINOIC ACID; UNCLASSIFIED DRUG; VITAMIN D;

ARTICLE; CANCER CELL CULTURE; CELL STRAIN CACO 2; CELL STRAIN LNCAP; COLON MUCOSA; CONTROLLED STUDY; ENDOCYTOSIS; HUMAN; HUMAN CELL; KIDNEY PARENCHYMA; MALE; NUTRIENT UPTAKE; PROSTATE EPITHELIUM; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN TRANSPORT;

EID: 84882358640     PISSN: 01635581     EISSN: 15327914     Source Type: Journal    
DOI: 10.1080/01635581.2013.805422     Document Type: Article

References (55)

1. Colston KW and Hansen CM: Mechanisms implicated in the growth regulatory effects of vitamin d in breast cancer. Endocrine-Related Cancer 9, 45-59, 2002.
2. Colston KW, James SY, Ofori-Kuragu EA, Binderup L, and Grant AG: Vitamin d receptors and anti-proliferative effects of vitamin d derivatives in human pancreatic carcinoma cells in vivo and in vitro. British Journal of Cancer 76, 1017-1020, 1997.
3. Garland CF, Grant WB, Mohr SB, Gorham ED, and Garland FC: What is the dose-response relationship between vitamin d and cancer risk? Nutr Rev 65, S91-S95, 2007.
4. Zinser G, Packman K, and Welsh J: Vitamin d(3) receptor ablation alters mammary gland morphogenesis. Development 129, 3067-3076, 2002.
5. Dackiw AP, Ezzat S, Huang P, Liu W, and Asa SL: Vitamin d3 administration induces nuclear p27 accumulation, restores differentiation, and reduces tumor burden in a mouse model of metastatic follicular thyroid cancer. Endocrinology 145, 5840-5846, 2004.
6. John EM, Schwartz GG, Dreon DM, and Koo J: Vitamin d and breast cancer risk: The nhanes i epidemiologic follow up study, 1971-1975 to 1992. Cancer Epidemiology Biomarkers Prevention 8, 399-406, 1999.
7. Ooi LL, Zhou H, Kalak R, Zheng Y, Conigrave AD, et al.: Vitamin d deficiency promotes human breast cancer growth in a murine model of bone metastasis. Cancer Research 70, 1835-1844, 2010.
8. Kawaura A, Takahashi A, Tanida N, Oda M, Sawada K, et al.: 1 alphahydroxyvitamin d3 suppresses colonic tumorigenesis induced by repetitive intrarectal injection of n-methyl-n-nitrosourea in rats. Cancer Lett 55, 149-152, 1990.
9. Grant WB: Relation between prediagnostic serum 25-hydroxyvitamin d level and incidence of breast, colorectal, and other cancers. J Photochem Photobiol B 101, 130-136, 2010.
10. Antico A, TampoiaM, Tozzoli R, and Bizzaro N: Can supplementation with vitamin d reduce the risk or modify the course of autoimmune diseases? A systematic review of the literature. Autoimmun Rev 12, 127-136, 2012.
11. Garland CF, Gorham ED, Mohr SB, and Garland FC: Vitamin d for cancer prevention: Global perspective. Ann Epidemiol 19, 468-483, 2009.
12. Mitri J, Muraru MD, and Pittas AG: Vitamin d and type 2 diabetes: A systematic review. Eur J Clin Nutr 65, 1005-1015, 2011.
13. Wang L, Song Y, Manson JE, Pilz S, Marz W, et al.: Circulating 25-hydroxy-vitamin d and risk of cardiovascular disease: A meta-analysis of prospective studies. Circ Cardiovasc Qual Outcomes 5, 819-829, 2012.
14. Wolpin BM, Ng K, Bao Y, Kraft P, Stampfer MJ, et al.: Plasma 25-hydroxyvitamin d and risk of pancreatic cancer. Cancer Epidemiol Biomarkers Prev 21, 82-91, 2012.
15. Nykjaer A, Dragun D, Walther D, Vorum H, Jacobsen C, et al.: An endocytic pathway essential for renal uptake and activation of the steroid 25(oh)hydroxyvitamin d3. Cell 96, 507-515, 1999.
16. Nykjaer A, Fyfe J, Kozyraki R, Leheste J-R, Jacobsen C, et al.: Cubilin dysfunction causes abnormal metabolism of the steroid hormone 25(oh) vitamin d3. Proceeding of the National Academy of Sciences USA 98, 13895-13900, 2001.
17. Nagai J, Christensen EI, Morris SM, Willnow TE, Cooper JA, et al.: Mutually dependent localization of megalin and dab2 in the renal proximal tubule. Am J Physiol Renal Physiol 289, F569-F576, 2005.
18. Rowling MJ, Kemmis CM, Taffany DA, and Welsh J: Megalinmediated endocytosis of vitamin d binding protein correlates with 25- hydroxycholecalciferol actions in human mammary cells. J Nutr 136, 2754-2759, 2006.
19. Chlon TM, Taffany DA, Welsh J, and Rowling MJ: Retinoids modulate expression of the endocytic partners megalin, cubilin, and disabled-2 and uptake of vitamin d-binding protein in human mammary cells. J Nutr 138, 1323-1328, 2008.
20. Marino M, Zheng G, Chiovato L, Pinchera A, Brown D, et al.: Role of megalin (gp330) in transcytosis of thyroglobulin by thyroid cells.Anovel function in the control of thyroid hormone release. J Biol Chem275, 7125-7137, 2000.
21. Cui S, Verroust PJ, Moestrup SK, and Christensen EI: Megalin/gp330 mediates uptake of albumin in renal proximal tubule. Am J Physiol 271, F900-F907, 1996.
22. Barth JL and Argraves WS: Cubilin and megalin: Partners in lipoprotein and vitamin metabolism. Trends Cardiovasc Med 11, 26-31, 2001.
23. Christensen EI andWillnow TE: Essential role of megalin in renal proximal tubule for vitamin homeostasis. J Am Soc Nephrol 10, 2224-2236, 1999.
24. Kemmis CM, Salvador SM, Smith KM, and Welsh J: Human mammary epithelial cells express cyp27b1 and are growth inhibited by 25-hydroxyvitamin d-3, the major circulating form of vitamin d-3. J Nutr 136, 887-892, 2006.
25. Wang L, Persons KS, Jamieson D, Flanagan JN, Hsu HH, et al.: Prostate 25-hydroxyvitamin d-1alpha-hydroxylase is up-regulated by suberoylanilide hydroxamic acid (saha), a histone deacetylase inhibitor. Anticancer Res 28, 2009-2013, 2008.
26. Hsu JY, Feldman D, McNeal JE, and Peehl DM: Reduced 1alphahydroxylase activity in human prostate cancer cells correlates with decreased susceptibility to 25-hydroxyvitamin d3-induced growth inhibition. Cancer Res 61, 2852-2856, 2001.
27. Welsh J, Wietzke JA, Zinser GM, Byrne B, Smith K, et al.: Vitamin d-3 receptor as a target for breast cancer prevention. The Journal of Nutrition 133, 2425S-2433S, 2003.
28. Welsh J, Simboli-Campbell M, Narvaez CJ, and Tenniswood M, Role of apoptosis in the growth inhibitory effects of vitamin d in mcf-7 cells. Adv Exp Med Biol 375, 45-52, 1995.
29. Rashid SF, Moore JS, Walker E, Driver PM, Engel J, et al.: Synergistic growth inhibition of prostate cancer cells by 1 alpha,25 dihydroxyvitamin d(3) and its 19-nor-hexafluoride analogs in combination with either sodium butyrate or trichostatin a. Oncogene 20, 1860-1872, 2001.
30. Cross HS, Pavelka M, Slavik J, and Peterlik M: Growth control of human colon cancer cells by vitamin d and calcium in vitro. J Natl Cancer Inst 84, 1355-1357, 1992.
31. Krill D, Stoner J, Konety BR, Becich MJ, and Getzenberg RH: Differential effects of vitamin d on normal human prostate epithelial and stromal cells in primary culture. Urology 54, 171-177, 1999.
32. Lappe JM, Travers-Gustafson D, Davies KM, Recker RR, and Heaney RP: Vitamin d and calcium supplementation reduces cancer risk: Results of a randomized trial. Am J Clin Nutr, 85, 1586-1591, 2007.
33. Garland C, Shekelle RB, Barrett-Connor E, Criqui MH, Rossof AH, et al.: Dietary vitamin d and calcium and risk of colorectal cancer: A 19-year prospective study in men. Lancet 1, 307-309, 1985.
34. Adamson PC: All-trans-retinoic acid pharmacology and its impact on the treatment of acute promyelocytic leukemia. Oncologist 1, 305-314, 1996.
35. http://www.ncbi.nlm.nih.gov/pubmed/17143048.
36. Grant WB: An ecological study of cancer mortality rates in California, 1950-64, with respect to solar uvb and smoking indices. Dermatoendocrinol 4, 176-182, 2012.
37. Grant WB: Ecological studies of the UVB-vitamin d-cancer hypothesis. Anticancer Res 32, 223-236, 2012.
38. Karam JA, Shariat SF, Huang HY, Pong RC, Ashfaq R, et al.: Decreased doc-2/dab2 expression in urothelial carcinoma of the bladder. Clin Cancer Res 13, 4400-4406, 2007.
39. Anupam K, Tusharkant C, Gupta SD, and Ranju R: Loss of disabled-2 expression is an early event in esophageal squamous tumorigenesis. World J Gastroenterol 12, 6041-6045, 2006.
40. Roland IH, Yang WL, Yang DH, Daly MB, Ozols RF, et al.: Loss of surface and cyst epithelial basement membranes and preneoplastic morphologic changes in prophylactic oophorectomies. Cancer 98, 2607-2623, 2003.
41. Fazili Z, Sun W, Mittelstaedt S, Cohen C, and Xu XX: Disabled-2 inactivation is an early step in ovarian tumorigenicity. Oncogene 18, 3104-3113, 1999.
42. Boscoe FP and Schymura MJ: Solar ultraviolet-b exposure and cancer incidence and mortality in the united states, 1993-2002. BMC Cancer, 6, 264, 2006.
43. Chen W, Clements M, Rahman B, Zhang S, Qiao Y, et al.: Relationship between cancer mortality/incidence and ambient ultraviolet b irradiance in china. Cancer Causes Control 21, 1701-1709, 2010.
44. Gugatschka M, Kiesler K, Obermayer-Pietsch B, Groselj-Strele A, Griesbacher A, et al.: Vitamin d status is associated with disease-free survival and overall survival time in patients with squamous cell carcinoma of the upper aerodigestive tract. Eur Arch Otorhinolaryngol 268, 1201-1204, 2011.
45. Ng K, Wolpin BM, Meyerhardt JA, Wu K, Chan AT, et al.: Prospective study of predictors of vitamin d status and survival in patients with colorectal cancer. Br J Cancer 101, 916-923, 2009.
46. Tretli S, Schwartz GG, Torjesen PA, and Robsahm TE: Serum levels of 25-hydroxyvitamin d and survival in norwegian patients with cancer of breast, colon, lung, and lymphoma: A population-based study. Cancer Causes Control 23, 363-370, 2012.
47. Vrieling A, Hein R, Abbas S, Schneeweiss A, Flesch-Janys D, et al.: Serum 25-hydroxyvitamin d and postmenopausal breast cancer survival: A prospective patient cohort study. Breast Cancer Res 13, R74, 2011.
48. Hathcock JN, Shao A, Vieth R, and Heaney R: Risk assessment for vitamin d. Am J Clin Nutr 85, 6-18, 2007.
49. Zehnder D, Bland R, Williams MC, McNinch RW, Howie AJ, et al.: Extrarenal expression of 25-hydroxyvitamin d(3)-1 alpha-hydroxylase. J Clin Endocrinol Metab 86, 888-894, 2001.
50. Albanes D, Mondul AM, Yu K, Parisi D, Horst RL, et al.: Serum 25-hydroxy vitamin d and prostate cancer risk in a large nested case-control study. Cancer Epidemiol Biomarkers Prev 20, 1850-1860, 2011.
51. Ma Y, Zhang P,Wang F, Yang J, Liu Z, et al.: Association between vitamin d and risk of colorectal cancer: A systematic review of prospective studies. J Clin Oncol 29, 3775-3782, 2011.
52. Shui IM, Mucci LA, Kraft P, Tamimi RM, Lindstrom S, et al.: Vitamin d-related genetic variation, plasma vitamin d, and risk of lethal prostate cancer: A prospective nested case-control study. J Natl Cancer Inst 104, 690-699, 2012.
53. Grant WB: Effect of interval between serum draw and follow-up period on relative risk of cancer incidence with respect to 25-hydroxyvitamin d level: Implications for meta-analyses and setting vitamin d guidelines. Dermatoendocrinol 3, 199-204, 2011.
54. Grant WB: Effect of follow-up time on the relation between prediagnostic serum 25-hydroxyvitamin d and all-cause mortality rate. Dermatoendocrinol 4, 198-202, 2012.
55. Lim U, Freedman DM, Hollis BW, Horst RL, Purdue MP, et al.: A prospective investigation of serum 25-hydroxyvitamin d and risk of lymphoid cancers. Int J Cancer 124, 979-986, 2009.